Storys zum Thema Pharmaindustrie

25.01.2019 – 15:32
Hovione
Hovione Issues $50 Million Bond
Lisbon (ots/PRNewswire) - Hovione has issued a bond of $50 million US dollars maturing in 2033. (Logo: https://mma.prnewswire.com/media/813604/Hovione_Logo.jpg ) The bond was arranged and subscribed by Banco BPI, S.A.. According to António Almeida, Hovione's CFO, "we issued this bond to strengthen our balance sheet as we embark in a new phase of significant capital expansion. We issued a USD denominated bond because the majority of our sales is in the USA". The bond is ...
mehr
23.01.2019 – 16:02
Philogen
Philogen Announces Collaboration With Celgene
Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development ...
mehr
23.01.2019 – 16:01
Philogen
Philogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation
Siena, Italy (ots/PRNewswire) - Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecule-based therapeutics utilizing Philochem's novel ...
mehr
07.01.2019 – 08:01
Daiichi Sankyo Europe GmbH
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...
mehr
03.01.2019 – 08:01
NORGINE B.V. and KOREA PHARMA CO., LTD.
NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea
Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...
mehr
10.12.2018 – 16:21
Merck Healthcare Germany GmbH
Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of ...
mehr
23.11.2018 – 14:40
Zentiva
Zentiva and PHOENIX Form Strategic Partnership in Europe
Prague (ots/PRNewswire) - Zentiva and PHOENIX joined forces this week for an inaugural Annual Partnership meeting in Prague to kick off a strategic partnership between the two healthcare companies in Europe. (Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg ) "At PHOENIX group we believe that Zentiva is an excellent fit for partnering at European level, thanks to their strong heritage, broad portfolio of ...
mehr
17.10.2018 – 17:36
Hovione
Hovione Increases Production Capacity
Loures, Portugal (ots/PRNewswire) - 'One Site Shop' expands to respond to growing demands Hovione announces plan to increase production capacity in oral dosage forms in Portugal, to strengthen the integrated offering. New commercial scale equipment for blending, tableting and coating will complement existing development small scale equipment. This decision to expand follows growing customer demand since, one year ago ...
mehr
17.10.2018 – 13:20
Merck Healthcare Germany GmbH
Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt
Darmstadt, Germany (ots/PRNewswire) - - Expansion of the pharma manufacturing site at Merck's headquarters supports growth of current and future portfolio of pharma medicines - New building dedicated to the packaging and shipping of Merck's pharma medicines in more than 90 countries - EUR63 million investment in new packaging center is part of wider EUR1 billion ...
mehr
21.08.2018 – 21:19
General Intermediates of Canada
General Intermediates of Canada, an Alberta Biotech Company, Receives Canadian Government Funding for Immuno-Oncology Project
Edmonton, Alberta (ots/PRNewswire) - Edmonton's GIC in pursuit of new immuno-oncology therapy Edmonton's General Intermediates of Canada Inc. (GIC) announced today that they have received conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) related to ...
mehr
26.07.2018 – 09:02
Merck Healthcare Germany GmbH
Merck Receives Recommendation for Approval in 21 EU Countries for the New Formulation of Euthyrox®
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - German Federal Institute for Drugs and Medical Devices (BfArM) recommends new formulation of Euthyrox® for approval in 21 EU countries - BfArM is acting as a representative of all 21 EU countries involved in the EU worksharing procedure Merck, a leading science and technology company, today ...
mehr
23.07.2018 – 14:13
Anima Biotech
Anima Biotech Announces an Exclusive Collaboration With Lilly for the Discovery and Development of Translation Inhibitors of Several Protein Targets
Bernardsville, New Jersey (ots/PRNewswire) - Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform. (Logo: https://mma.prnewswire.com/media/721538/Anima_Biotech_Logo.jpg ...
mehr
14.07.2015 – 18:48
Zambon GmbH
Zambon Expands in Europe Acquiring Nigaard
Milan (ots/PRNewswire) - The deal will speed up the commercialization of Xadago(R) for the treatment of Parkinson's Disease Nigaard is a pharmaceutical company well established in Denmark, Norway, Sweden, Iceland and Finland Zambon S.p.A., an international pharmaceutical company strongly committed to the Central Nervous System (CNS) therapeutic area and the Respiratory area with a focus on Rare Diseases, announced today ...
mehr

Vorherige1234567